Serum Institute of India (SII) Institute
.jpeg)
Serum Institute is vaccine manufacturer by number of doses produced.
Serum Institute of India (SII) is collaborating with Codagenix, a US-based biopharmaceutical company, to develop a cure for coronavirus using a vaccine strain similar to the original virus. The vaccine is currently in the pre-clinical testing phase, while human trials are expected to commence in the next six months. SII is expected to launch the vaccine in the market by early 2022.
Serum Institute of India (SII) is collaborating with Codagenix, a US-based biopharmaceutical company, to develop a cure for coronavirus using a vaccine strain similar to the original virus. The vaccine is currently in the pre-clinical testing phase, while human trials are expected to commence in the next six months. SII is expected to launch the vaccine in the market by early 2022.
Technology:
Research and Academia
Industry:
COVID
Headquarters:
Pune, Maharashtra, India
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership